文献速递淋巴瘤

伴MYC和BCL2重排的高级别B细胞淋巴瘤及表达暗区特征弥漫大B细胞淋巴瘤的中枢神经系统复发

CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL.
PubMed 文献 · Blood · 2025-01-01

该研究基于完整荧光原位杂交检测的人群队列,报告伴MYC和BCL2重排的高级别B细胞淋巴瘤(HGBCL-DH-BCL2)2年中枢神经系统复发风险为6.8%,复发早、以软脑膜为主且多伴全身复发。表达暗区基因表达特征(DZsig)的DLBCL形态肿瘤中枢神经系统复发风险独立于HGBCL-DH-BCL2状态,DZsig可细化GCB-DLBCL的风险分层。

要点

  • HGBCL-DH-BCL2的2年中枢神经系统复发风险为6.8%,低于既往报告。
  • DZsig+肿瘤2年中枢神经系统复发风险6.4%,独立于HGBCL-DH-BCL2状态。
  • DZsig阴性GCB-DLBCL中枢神经系统复发罕见(2年1.4%),且均为脑实质受累。

核心结论

  • HGBCL-DH-BCL2的中枢神经系统复发风险低于既往报告,DZsig可细化GCB-DLBCL的风险分层。

研究设计与样本

  • 基于人群的队列研究,采用完整荧光原位杂交检测,报告HGBCL-DH-BCL2及表达DZsig的DLBCL形态肿瘤的中枢神经系统复发率。

主要发现

  • HGBCL-DH-BCL2的2年中枢神经系统复发风险为6.8%。
  • 中枢神经系统复发出现早,以软脑膜为主(73%),并与全身复发同时发生(64%)。
  • 高危中枢神经系统国际预后指数(CNS-IPI)和一致性骨髓受累与HGBCL-DH-BCL2中枢神经系统复发风险升高相关。
  • 「细化细胞起源」分类将20%具有生发中心B细胞样表型的DLBCL形态肿瘤(GCB-DLBCL)基于DZsig表达归入DZsig+亚组。
  • DZsig+的2年中枢神经系统复发风险为6.4%,独立于HGBCL-DH-BCL2状态,并进一步按CNS-IPI分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2), or "double-hit lymphoma," has been associated with a high risk of central nervous system (CNS) relapse. However, historic estimates are impacted by selection bias. We report CNS relapse rates associated with HGBCL-DH-BCL2 from a population-based cohort with complete fluorescence in situ hybridization testing, as well as diffuse large B-cell lymphoma morphology (DLBCL) tumors expressing the dark-zone gene expression signature (DZsig), which was originally derived from HGBCL-DH-BCL2. The 2-year CNS relapse risk in HGBCL-DH-BCL2 was 6.8%. CNS relapses were early, predominantly leptomeningeal (73%), and co-occurred with systemic relapse (64%). High-risk CNS International Prognostic Index (CNS-IPI) and concordant bone marrow involvement were associated with an elevated CNS relapse risk in HGBCL-DH-BCL2. The "refined cell-of-origin" classification assigned 20% of DLBCL morphology tumors with germinal center B-cell-like phenotype (GCB-DLBCL) into a distinct subgroup based on DZsig expression (DZsig+). CNS relapse risk in DZsig+ (2 year: 6.4%) was independent of HGBCL-DH-BCL2 status and was further stratified by the CNS-IPI. CNS relapse in DZsig-negative GCB-DLBCL was rare (2-year risk, 1.4%; P = .04 vs DZsig+) and exclusively parenchymal. Altogether, the CNS relapse risk in HGBCL-DH-BCL2 is lower than previously reported, and DZsig refines risk stratification in GCB-DLBCL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Alduaij W, Jiang A, Villa D, et al. CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL. Blood. 2025. PMID: 39441916. doi:10.1182/blood.2024025725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。